login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NOVO-NORDISK A/S-SPONS ADR (NVO) Stock News
USA
-
New York Stock Exchange
- NYSE:NVO -
US6701002056
-
ADR
47.9699
USD
-0.12 (-0.25%)
Last: 12/22/2025, 2:00:07 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NVO Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Chartmill
Novo Nordisk (NYSE:NVO) Identified as a 'Decent Value' Stock with Strong Fundamentals
16 days ago - By: Chartmill
Novo Nordisk (NYSE:NVO) Embodies Quality Investing Principles
10 hours ago - By: The Motley Fool
- Mentions:
PFE
LLY
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
3 days ago - By: Zacks Investment Research
- Mentions:
LLY
CRMD
CSTL
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
4 days ago - By: The Motley Fool
Prediction: 1 Healthcare Giant Set to Soar in 2026
4 days ago - By: Zacks Investment Research
- Mentions:
LLY
VKTX
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
5 days ago - By: Zacks Investment Research
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
5 days ago - By: Zacks Investment Research
- Mentions:
PFE
LLY
SMMT
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
7 days ago - By: Zacks Investment Research
- Mentions:
LLY
VKTX
GPCR
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
7 days ago - By: Zacks Investment Research
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
12 days ago - By: BusinessInsider
- Mentions:
GS
LLY
LLY and NOVO: Goldman Sachs Weighs In on the Top Obesity Stocks to Watch in 2026
12 days ago - By: Zacks Investment Research
- Mentions:
LLY
VKTX
GPCR
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
12 days ago - By: Zacks Investment Research
- Mentions:
PFE
LLY
VKTX
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
13 days ago - By: Zacks Investment Research
- Mentions:
SNY
BMY
TEVA
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
13 days ago - By: Zacks Investment Research
- Mentions:
LLY
VKTX
GPCR
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
13 days ago - By: Stocktwits
- Mentions:
LLY
WVE
THNR
The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In
14 days ago - By: Stocktwits
- Mentions:
GPCR
LLY
Why Did Structure Therapeutics Stock Surge Pre-Market Today?
18 days ago - By: Stocktwits
- Mentions:
SPY
DIA
PFE
LLY
Trump Administration Eases Investment Deadlines For Large Pharma Companies: Report
18 days ago - By: Zacks Investment Research
- Mentions:
LLY
VKTX
ADVM
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock
Please enable JavaScript to continue using this application.